Education
About Us
Working with TipRanks
Follow Us
ImmunoCellular Therapeutics (IMUC)
OTHER OTC:IMUC
IMUC Stock Chart & Stats
$0.13
$0.00(0.00%)
At close: 4:00 PM EST
$0.13
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.01 - $0.34
Previous CloseN/A
Volume63.00
Average Volume (3M)9.99K
Market Cap
$20.28M
Enterprise ValueN/A
Total Cash (Recent Filing)$613.24K
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta0.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,270,750
10 Day Avg. Volume23,818
30 Day Avg. Volume9,991
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-31.45
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IMUC FAQ
What was ImmunoCellular Therapeutics’s price range in the past 12 months?
ImmunoCellular Therapeutics lowest stock price was $0.01 and its highest was $0.34 in the past 12 months.
What is ImmunoCellular Therapeutics’s market cap?
ImmunoCellular Therapeutics’s market cap is $20.28M.
When is ImmunoCellular Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunoCellular Therapeutics’s earnings last quarter?
Currently, no data Available
Is ImmunoCellular Therapeutics overvalued?
According to Wall Street analysts ImmunoCellular Therapeutics’s price is currently Overvalued.
Does ImmunoCellular Therapeutics pay dividends?
ImmunoCellular Therapeutics does not currently pay dividends.
What is ImmunoCellular Therapeutics’s EPS estimate?
ImmunoCellular Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoCellular Therapeutics have?
ImmunoCellular Therapeutics has 113,270,750 shares outstanding.
What happened to ImmunoCellular Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunoCellular Therapeutics?
Currently, no hedge funds are holding shares in IMUC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmunoCellular Therapeutics
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company, which engages in the development of drugs with the potential to transform therapeutic paradigms. Its pipeline includes EOM613 and EOM147. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.
Technical Analysis
Xenetic Biosciences
―
Adial Pharmaceuticals
―
VYNE Therapeutics
―
IN8bio
―
Bolt Biotherapeutics
―